Meeting
2023 ASCO Annual Meeting
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Authors
Laura S. Samples
Fred Hutchinson Cancer Research Center, Seattle, WA
Laura S. Samples , Hossein Sadrzadeh , Matthew J. Frigault , Caron Alyce Jacobson , Mehdi Hamadani , Ashwath Gurumurthi , Paolo Strati , Roni Shouval , Peter A. Riedell , Saurabh Dahiya , Jean Yared , Michael D. Jain , Frederick L. Locke , Lori Ann Leslie , Narendranath Epperla , Monalisa Ghosh , Alan Skarbnik , Brian T Hill , Manali K. Kamdar , Mazyar Shadman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7571)
DOI
10.1200/JCO.2023.41.16_suppl.7571
Abstract #
7571
Poster Bd #
122
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Autologous hematopoietic stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma.
First Author: Xiuxiu Yang
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
First Author: Peihua Lu
Poster
2023 ASCO Annual Meeting
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).
First Author: Matthew J. Frigault